[ORGANIZATION]
GLP-1 drugs
Featured in 2 tracked stories · first seen
Situations
Novo Nordisk pivots strategy to counter patent cliff
112 clusters · 548 sources · last updated
Latest: Novo Nordisk faces intense competition in obesity drug market
Novo Nordisk is implementing a strategic reset to address long-term growth concerns and the looming patent expiration of semaglutide in the early 2030s. To diversify its portfolio and counter competition from Eli Lilly,
PMOS: Cancer Risks, Symptoms, and Cognitive Health
29 clusters · 146 sources · last updated
Latest: PMOS linked to increased dementia and Alzheimer's risk
Following the May 2026 international consensus renaming polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome (PMOS), new research and clinical developments have emerged regarding its management and risks